IDM Pharma, Inc. (IDMI) updated shareholders on results from the Phase 2 UVIDEM® (IDD-3) melanoma vaccine clinical trial (DC-MEL-202). These updated clinical trial results have shown that the investigational agent “UVIDEM” induction into human immune systems was well tolerated with patients suffering advanced melanoma.
The data was presented during a poster session at the International Society for Biological Therapy of Cancer (iSBTc) annual meeting today in Boston.
“There is a distinct need in the medical community for new treatments for metastatic melanoma,” said Dr. Antoni Ribas, associate professor of medicine and surgery at UCLA and associate director of tumor immunology at the Jonsson Comprehensive Cancer Center. “The early analysis of data from the Phase 2 clinical trial with IDM Pharma’s cancer vaccine, UVIDEM, has demonstrated that a small portion of patients is able to gain control of their disease through stimulating their bodies’ natural defenses — their immune system cells, and they were able to do so with minimal side effects.”
“The available results of this trial are very encouraging given the difficult-to-treat patient population,” said Timothy P. Walbert, president and chief executive officer, IDM Pharma, Inc. “We are confident in the potential of this product to fulfill the unmet medical need and look forward to the completion of our Phase 2 program as well as the initiation of the Phase 3 program.”
Let us hear your thoughts below: